Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
RIGL 
Rigel Pharmaceuticals Inc (RIGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/11/2025: RIGL (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $49.6
1 Year Target Price $49.6
| 1 | Strong Buy |
| 1 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -10.02% | Avg. Invested days 28 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 763.26M USD | Price to earnings Ratio 6.65 | 1Y Target Price 49.6 |
Price to earnings Ratio 6.65 | 1Y Target Price 49.6 | ||
Volume (30-day avg) 6 | Beta 1.11 | 52 Weeks Range 14.63 - 52.24 | Updated Date 12/11/2025 |
52 Weeks Range 14.63 - 52.24 | Updated Date 12/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 6.32 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 40.17% | Operating Margin (TTM) 40.91% |
Management Effectiveness
Return on Assets (TTM) 38.93% | Return on Equity (TTM) 220.06% |
Valuation
Trailing PE 6.65 | Forward PE 7.94 | Enterprise Value 671935399 | Price to Sales(TTM) 2.71 |
Enterprise Value 671935399 | Price to Sales(TTM) 2.71 | ||
Enterprise Value to Revenue 2.38 | Enterprise Value to EBITDA 5.4 | Shares Outstanding 18151344 | Shares Floating 17898677 |
Shares Outstanding 18151344 | Shares Floating 17898677 | ||
Percent Insiders 2.62 | Percent Institutions 84.2 |
Upturn AI SWOT
Rigel Pharmaceuticals Inc
Company Overview
History and Background
Rigel Pharmaceuticals, Inc. was founded in 1996. It is a biotechnology company focused on discovering and developing novel, small-molecule drugs for immunological and hematological disorders, as well as cancer. Rigel's early focus was on kinase inhibitors.
Core Business Areas
- Immunology and Hematology: Focuses on developing and commercializing treatments for immune and blood-related disorders.
- Oncology: Developing therapies for various types of cancer, leveraging Rigel's kinase inhibitor expertise.
- Commercialization and Partnerships: Commercializing its own products and collaborating with other pharmaceutical companies.
Leadership and Structure
The company is led by a CEO and executive team with expertise in drug development and commercialization. The organizational structure includes departments for research and development, clinical trials, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- TAVALISSEu00ae (fostamatinib disodium hexahydrate): A spleen tyrosine kinase (SYK) inhibitor approved for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to prior treatment. In Q1 2024, TAVALISSE revenue was reported at $24.6M. Competitors include products like Amgen's Romiplostim (Nplate) and Novartis' Eltrombopag (Promacta).
- Rezlidhia (olutasidenib): An oral targeted therapy approved for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation. Rigel licensed development and commercialization rights for Rezlidhia from Forma Therapeutics. Competitors include other AML therapies with IDH1 inhibitors such as Tibsovo.
Market Dynamics
Industry Overview
The biotechnology industry is characterized by high research and development costs, long regulatory approval timelines, and intense competition. The market for treatments for immunological and hematological disorders, as well as cancer, is large and growing.
Positioning
Rigel is positioned as a specialty pharmaceutical company focused on developing and commercializing niche therapies for specific patient populations. Its competitive advantage lies in its expertise in kinase inhibitor development and its ability to identify and develop targeted therapies.
Total Addressable Market (TAM)
The combined TAM for ITP and AML is estimated to be in the billions of dollars. Rigel is positioned to capture a portion of this market with its approved therapies.
Upturn SWOT Analysis
Strengths
- Approved products (TAVALISSE, Rezlidhia)
- Experienced management team
- Strong pipeline of clinical candidates
- Expertise in kinase inhibitor development
Weaknesses
- Reliance on a limited number of products
- High R&D expenses
- Dependence on partnerships
- Commercial execution risks
Opportunities
- Expansion of TAVALISSE indications
- Development of new therapies for other diseases
- Partnerships with larger pharmaceutical companies
- Acquisition of complementary technologies
Threats
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Patent expiration
- Economic downturns
Competitors and Market Share
Key Competitors
- AMGN
- NVS
- BMY
Competitive Landscape
Rigel faces competition from established pharmaceutical companies with larger resources. Its advantage lies in its specialized focus and expertise.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the approval and commercialization of TAVALISSE.
Future Projections: Future growth is projected to be driven by expansion of existing product indications, and new partnerships.
Recent Initiatives: Recent initiatives include expanding the TAVALISSE market through new partnerships in other regions and developing new therapies for other diseases.
Summary
Rigel Pharmaceuticals is a biotechnology company with revenue from two key drugs: Tavalisse and Rezlidhia. They have strong expertise in kinase inhibitor development, but are reliant on a limited number of products. Opportunities exist in expanding existing product indications and forming new partnerships. They must watch out for the increasing competition and regulatory hurdles in the biotech industry.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, press releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rigel Pharmaceuticals Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2000-11-29 | President, CEO & Director Mr. Raul R. Rodriguez | ||
Sector Healthcare | Industry Biotechnology | Full time employees 162 | Website https://www.rigel.com |
Full time employees 162 | Website https://www.rigel.com | ||
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.